A multiplex assay combining insulin, GAD, IA-2 and transglutaminase autoantibodies to facilitate screening for pre-type 1 diabetes and celiac disease

Journal of Immunological Methods

Volumn 430, Issue , 2016, Pages 28-32

  Zhao, Zhiyuan ^a   Miao, Dongmei ^a   Michels, Aaron ^a   Steck, Andrea ^a   Dong, Fran ^a   Rewers, Marian ^a   Yu, Liping ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

Assay; Autoantibodies; Celiac disease; Diabetes

Indexed keywords

AUTOANTIBODY; GLUTAMATE DECARBOXYLASE; INSULIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; GLUTAMATE DECARBOXYLASE 2; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE;

ANTIBODY DETECTION; ARTICLE; BLOOD VOLUME; CELIAC DISEASE; CHEMOLUMINESCENCE; CONTROLLED STUDY; ENZYME ASSAY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RADIOASSAY; SENSITIVITY AND SPECIFICITY; ADULT; BLOOD; DEVICES; DIABETES MELLITUS, TYPE 1; FEMALE; IMMUNOLOGY; LUMINESCENCE; MALE; MASS SCREENING; MIDDLE AGED; PROCEDURES;

ADULT; AUTOANTIBODIES; CELIAC DISEASE; DIABETES MELLITUS, TYPE 1; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; INSULIN; LUMINESCENT MEASUREMENTS; MALE; MASS SCREENING; MIDDLE AGED; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 8; SENSITIVITY AND SPECIFICITY; TRANSGLUTAMINASES;

EID: 84959121146     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2016.01.011     Document Type: Article

References (25)

1. AGA Institute AGA Institute Medical position statement on the diagnosis and management of celiac disease. Gastroenterology 2006, 131:1977-1980. (PMID: 17087935).
2. Anon The environmental determinants of diabetes in the young (TEDDY) study. Ann. N. Y. Acad. Sci. 2008, 1150:1-13. (PMID: 19120261 PMCID: PMC2886800).
3. Atkinson M.A., Eisenbarth G.S., Michels A.W. Type 1 diabetes. Lancet 2014, 383:69-82. (PMID: 23890997).
4. Bao F., Yu L., Babu S., et al. One third of HLA DQ2 homozygous patients with type 1 diabetes express celiac disease associated transglutaminase autoantibodies. J. Autoimmun. 1999, 13:143-148. (PMID: 10441179).
5. Bautista K., Waugh K., Baxter J., Yu L., Rewers M., Gesualdo P. Feasibility of screening for type 1 diabetes and celiac disease in a pediatric clinic setting. Pediatr. Diabetes 2015, [Epub ahead of print]PMID: 26251221. 10.1111/pedi.12301.
6. Benson B.C., Mulder C.J., Laczek J.T. Anti-gliadin antibodies identify celiac patients overlooked by tissue transglutaminase antibodies. Hawaii J. Med. Public Health 2013, 72(9 Suppl. 4):14-17. (PMCID: PMC3764583).
7. Bingley P.J. Clinical applications of diabetes antibody testing. J. Clin. Endocrinol. Metab. 2010, 95:25-33. (PMID: 19875480).
8. Bonifacio E., Yu L., Williams A.K., et al. Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia. J. Clin. Endocrinol. Metab. 2010, 95:3360-3367. (PMID: 20444913).
9. Chiang J.L., Kirkman M.S., Laffel L.M.B., et al. Type 1 diabetes through the life span: a position statement of the American Diabetes Association[J]. Diabetes Care 2014, 37:2034-2054.
10. Fasano A., Berti I., Gerarduzzi T., et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study[J]. Arch. Intern. Med. 2003, 163:286.
11. Husby S., Koletzko S., Korponay-Szabó I.R., ESPGHAN Working Group on Coeliac Disease Diagnosis; ESPGHAN Gastroenterology Committee; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J. Pediatr. Gastroenterol. Nutr. 2012, 54:136-160. (PMID: 22197856).
12. Liu E., Lee H.S., Aronsson C.A., TEDDY Study Group, et al. Risk of pediatric celiac disease according to HLA haplotype and country. N. Engl. J. Med. 2014, 371:42-49. (PMID: 24988556).
13. Lohi S., Mustalahti K., Kaukinen K., et al. Increasing prevalence of coeliac disease over time. Aliment. Pharmacol. Ther. 2007, 26:1217-1225. (PMID: 17944736).
14. Miao D., Guyer K.M., Dong F., et al. GAD65 autoantibodies detected by electrochemiluminescence (ECL) assay identify high risk for type 1 diabetes. Diabetes 2013, 62:4174-4178. (PMID: 23974918).
15. Miao D., Steck A., Zhang L., et al. The type 1 diabetes TrialNet study group. electrochemiluminescence assays for insulin and GAD autoantibodies improve prediction of type 1 diabetes risk. Diabetes Technol. Ther. 2014, 17:119-127. (PMID: 25562486).
16. Schlosser M., Mueller P.W., Törn C., Bonifacio E., PJ Bingley, Participating Laboratories Diabetes antibody standardization program: evaluation of assays for insulin autoantibodies. Diabetologia 2010, 53:2611-2620. (PMID: 20871974).
17. Sosenko J.M., Skyler J.S., Palmer J.P., Diabetes Prevention Trial-Type 1 and Type 1 Diabetes TrialNet Study Groups, et al. A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in diabetes prevention trial-type 1 (DPT-1) participants. Diabetes Care 2011, 34:2435-2437. (PMID: 21911777 PMCID: PMC3198298).
18. Sosenko J.M., Skyler J.S., Palmer J.P., Type 1 Diabetes TrialNet and the Diabetes Prevention Trial-Type 1 Study Groups, et al. The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. Diabetes Care 2013, 36:2615-2620. (PMID: 23818528 PMCID: PMC3747899).
19. Steck A.K., Johnson K., Barriga K.J., et al. Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes: diabetes autoimmunity study in the young. Diabetes Care 2011, 34:1397-1399. (PMID: 21562325 PMCID: PMC3114355).
20. Vehik K., Haller M.J., Beam C.A., DPT-1 Study Group, et al. Islet autoantibody seroconversion in the DPT-1 study: justification for repeat screening throughout childhood. Diabetes Care 2011, 34:358-362. (PMID: 21270193 PMCID: PMC3024349).
21. Yu L., Boulware D.C., Beam C.A., Type 1 Diabetes TrialNet Study Group, et al. Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies. Diabetes Care 2012, 35:1213-1218. (PMID: 22446173 PMCID: PMC3357246).
22. Yu L., Dong F., Dongmei M., et al. Proinsulin/insulin autoantibodies measured with electrochemiluminescent assay are the earliest indicator of prediabetic islet autoimmunity. Diabetes Care 2013, 36:2266-2270. (PMID: 23423694).
23. Yu L., Miao D., Scrimgeour L., Johnson K., Rewers M., Eisenbarth G.S. Distinguishing persistent insulin autoantibodies with differential risk: non-radioactive bivalent proinsulin/insulin autoantibody assay. Diabetes 2012, 61:179-186. (PMID: 22124462).
24. Yu L., Robles D.T., Abiru N., et al. Early expression of anti-insulin autoantibodies of man and the NOD mouse: evidence for early determination of subsequent diabetes. Proc. Natl. Acad. Sci. 2000, 97:1701-1706. (PMID: 10677521).
25. Ziegler A.G., Rewers M., Simell O., et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013, 309:2473-2479. (PMID: 23780460).